On March 11, 2021 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, reported that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in the Emerging Growth Virtual Conference hosted by M Vest LLC and Maxim Group, LLC on Wednesday, March 17, 2021 (Press release, Sellas Life Sciences, MAR 11, 2021, View Source [SID1234576481]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the SELLAS corporate presentation, Dr. Stergiou will participate in the Cancer Vaccines Panel hosted by Jason McCarthy, PhD, Maxim Senior Managing Director, Biotechnology (Research Analyst) on Wednesday, March 17 at 1:00 p.m. ET. The panel will be an informative discussion on the market opportunity for cancer vaccines as well as upcoming milestones from the participating companies.

To attend, register here. An archived replay will be available on SELLAS’ investor relations website at www.sellaslifesciences.com/investors.

For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your M Vest / Maxim representative directly, or KCSA Strategic Communications at [email protected].